Baseline soluble MICA levels act as a predictive biomarker for the efficacy of regorafenib treatment in colorectal cancer

BACKGROUND: To evaluate the effect of regorafenib on soluble MHC class I polypeptide-related sequence A (MICA) (sMICA) level in vitro. In addition, we clinically examined whether its plasma levels were associated with regorafenib activity in terms of progression-free survival (PFS) in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Arai, Jun, Otoyama, Yumi, Fujita, Ken-ichi, Goto, Kaku, Tojo, Masayuki, Katagiri, Atsushi, Nozawa, Hisako, Kubota, Yutaro, Takahashi, Takehiro, Ishida, Hiroo, Tsunoda, Takuya, Matsumoto, Natsumi, Ogawa, Keita, Nakagawa, Ryo, Muroyama, Ryosuke, Kato, Naoya, Yoshida, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019943/
https://www.ncbi.nlm.nih.gov/pubmed/35443621
http://dx.doi.org/10.1186/s12885-022-09512-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019943/
https://www.ncbi.nlm.nih.gov/pubmed/35443621
http://dx.doi.org/10.1186/s12885-022-09512-5

Ejemplares similares